GlassScriptPhysician profile
Maria Tulpan
NPI 1598766560
$6,149.85
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,345 · 2020: $1,289 · 2021: $515.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $923.33 | 2019-2021 | |
| Lilly USA, LLC | $895.24 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $827.62 | 2019-2021 | |
| Mannkind Corporation | $601.03 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $475.27 | 2019-2021 | |
| Abbvie INC. | $467.68 | 2019-2021 | |
| Radius Health, INC. | $356.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.61 | 2019-2021 | |
| Senseonics, Incorporated | $193.00 | 2019 | |
| Merck Sharp & Dohme LLC | $189.21 | 2019-2020 | |
| Amgen INC. | $188.96 | 2019-2021 | |
| Edwards Lifesciences Corporation | $164.89 | 2021 | |
| Janssen Pharmaceuticals, INC | $148.38 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $74.46 | 2019-2020 | |
| Amarin Pharma, INC. | $63.24 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $57.90 | 2019-2021 | |
| Medtronic Minimed, INC. | $41.70 | 2019 | |
| Ibsa Pharma INC. | $34.52 | 2019 | |
| Corcept Therapeutics | $23.48 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.89 | 2019 | |
| Insulet Corporation | $21.63 | 2020 | |
| Abbott Laboratories | $18.69 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.64 | 2019 | |
| Aytu Biopharma, INC. | $13.83 | 2019 | |
| Shire North American Group INC | $13.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Tulpan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.